Winning KERX Stock Forecast: Keryx Biopharmaceuticals Continues To Save Its Patients And Surges With 19.55% In 7 Days
“Revenue growth in the first quarter of 2018, as compared to the first quarter of 2017, was driven by an increase in Auryxia prescription and tablet demand, partially offset, by a reduction in the net price realized per tablet due to an increase in our gross-to-net adjustment”
– Scott Holmes, Senior Vice President and CFO of Keryx Biopharmaceuticals
Over the 7 days period from May 9th to May 16th, 2018 KERX stock price saw significant price jump of more than 19%. The overall KERX stock performance indicators for the last quarter suggest that this may be
